Feedback / Questions
BCMA-CD38 bispecific CAR-T cell therapy - Shengyan Pharmaceutical Technology
https://www.targetedonc.com/conference/ash-2019/car-tcell-therapy-targeting-bcma-and-cd38-induces-positive-responses-in-multiple-myeloma
 
Dec 7, 2019
 
SHARE THIS
  • Print
  • Email
  • More sharing
    Reddit
    StumbleUpon
    Delicious